Onivyde, also known as irinotecan liposome injection, works by delivering irinotecan, a topoisomerase I inhibitor, directly to tumor cells [1].
How does Onivyde deliver irinotecan to cancer cells?
Onivyde utilizes a liposomal encapsulation technology. The irinotecan is enclosed within tiny lipid spheres, or liposomes. This formulation allows for a sustained release of the drug into the bloodstream and tumor microenvironment [1].
What is irinotecan and how does it fight cancer?
Irinotecan is a derivative of camptothecin, a naturally occurring alkaloid. It functions as a topoisomerase I inhibitor. Topoisomerase I is an enzyme essential for DNA replication and transcription. By inhibiting this enzyme, irinotecan prevents cancer cells from replicating their DNA and ultimately leads to cell death [1].
When might doctors prescribe Onivyde?
Onivyde is indicated for use in combination with other chemotherapy agents for patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based therapy [1].
What are the potential side effects of Onivyde?
Common side effects reported with Onivyde include diarrhea, fatigue, vomiting, nausea, fever, and decreased appetite [1].
How does Onivyde's mechanism differ from other pancreatic cancer treatments?
Onivyde's mechanism of action is centered on the targeted delivery of irinotecan via liposomal encapsulation, aiming for sustained drug release and reduced systemic toxicity compared to conventional irinotecan injections [1]. Other treatments for pancreatic cancer may involve different chemotherapy agents, targeted therapies, or immunotherapies, each with distinct mechanisms of action.
Where can I find information on Onivyde patents and exclusivity?
Information regarding drug patents, including those for Onivyde, and their expiry dates can be found on resources like DrugPatentWatch.com [2].
---
1. Onivyde Prescribing Information.
2. DrugPatentWatch.com